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Abstract
Introduction: Febrile neutropenia (FN) is a common complication of the intensive treatment
strategies used in pediatric oncology. By close adherence to high-quality guidelines, which can be
evaluated by indicators, the burden of FN can potentially be reduced.
Objectives:The aims of this studywere tripartite—(1) to develop structure, process, and outcome
indicators, (2) to evaluate the implementation of the Dutch Childhood Oncology Group (DCOG)
guideline on FN, and (3) to produce baseline measures on local quality of FN care (in the north of
the Netherlands).
Methods: Seven indicators derived from the DCOG guideline were developed. Regarding struc-
ture indicators, we gathered information from all local centers providing care for children with
cancer (n = 9). Regarding process and outcome indicators, we collected individual patient data
from one academic and two shared-care hospitals. Children (<18 years) were included if they had
been diagnosedwith cancer in 2014 or 2015 and had suffered from FN.
Results: Six out of nine hospitals used the DCOG guideline on FN and three hospitals used an
outdated supportive care handbook. Regarding individual patient data, we included 119 FN
episodes in 59 patients. All FN episodes without focus were initially treated with guideline-based
antibiotics. Of all FN episodes, 18.5% resulted in intensive care unit (ICU) admittance. Cumulative
incidence of death during FNwas 1.74%.
Conclusion:Adherence to the DCOG guideline at the individual patient level was excellent. How-
ever, indicators concerning mortality and ICU admittances showed that FN still has devastating
consequences. Subsequently, we will implement these indicators nationwide in order to improve
FN care.
K EYWORDS
clinical practice guidelines, febrile neutropenia, indicators, pediatric oncology, supportive care
1 INTRODUCTION
Cure rates of children with cancer have increased from 20% in the
1960s to a current survival of 80% in developed countries.1,2 This
substantial increase is mainly due to higher specific diagnostic tools
Abbreviations: ALL, acute lymphoblastic leukemia; BAL, broncho-alveolar lavage; CI, confidence interval; CPG, clinical practice guideline; DCOG, Dutch ChildhoodOncology Group; EPR,
electronic patient records; FN, febrile neutropenia; HRCT, high-resolution computed tomography; ICU, intensive care unit; MREC, medical research ethics committee
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and more intensive types of therapy. The drawback of these thera-
pies is the associationwith relatively higher rates of treatment-related
morbidity andmortality.3 A recent Canadian study showed that one in
every four deaths in children with acute lymphoblastic leukemia (ALL)
was related to treatment.4 The major cause for treatment-related
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mortality is febrile neutropenia (FN) and associated infections.5,6 A
possibleway to lower theburdenof FN is byoptimizing supportive care
and by close adherence to corresponding high-quality guidelines.
Clinical practice guidelines (CPGs) are guidelines based on a sys-
tematic appraisal of the best available evidence, and can assist prac-
titioners’ decision making in order to limit practice variation and to
improve clinical care.7,8 Currently, only few international high-quality
pediatric oncology supportive care guidelines exist. Among those are
CPGs on FN and on nausea and vomiting.9,10 In the Netherlands,
guidance for supportive care is provided by the Dutch Childhood
Oncology Group (DCOG) guidelines, which are based on the avail-
able international CPGs combined with local expert consensus. Nev-
ertheless, despite the existence of these guidelines, a recent survey
showed that 75% of examined supportive care was discordant in the
Netherlands.11 This might imply suboptimal care, which may result
in increased morbidity and mortality.12 Therefore, it is of the utmost
importance to adequately implement guidelines, and evaluate this by
means of indicators.13
Indicators are measurable items and are used as guides to moni-
tor, evaluate, and improve the quality of patient care, clinical support
services, andorganizational function that affect patient outcomes.13,14
Three types of indicators havebeen identified,whichdenote attributes
of settings in which care occurs (structure), activities and processes
that belong to giving and receiving care (process), and states of health
or events that follow care (outcome).14 The development of indicators
is ideally done in line with evidence-based recommendations or by a
systematic review of available literature, but can also be accomplished
by a (multi-) expert consensus process.14 The main objectives of this
study focusing on FN were (1) to develop structure, process, and out-
come indicators derived from the DCOG guidelines on FN, and (2) to




Figure 1 shows a flowchart of the development of indicators. A mul-
tidisciplinary project group, consisting of two pediatric oncologists
(W.J.E.T.,M.D.W.), a pediatric epidemiologist (L.C.M.K.), and two clinical
researchers (E.A.H.L., S.B.), prioritized the main topics of the DCOG
guideline on FN using a simple consensus process (see Supplementary
Material S1 for a full list of extracted recommendations). Due to
the retrospective nature of this study, we had to consider whether
information needed for the indicators was documented and therefore
available. If not, those recommendations could not be used to develop
indicators. Firstly, structure indicators were developed to gather
information on the use of the DCOG FN guideline to verify whether
hospitals met the basic conditions. Secondly, process indicators were
developed to evaluate the provided supportive care. Thirdly, outcome
indicators were used to measure important undesirable outcomes
of FN. For rate-based indicators, numerators and denominators
were determined. After development, the DCOG multiprofes-
sional supportive care working group (10 professionals including
F IGURE 1 Flowchart of the development of indicators
pediatric oncologists, nurses, and an epidemiologist) approved the
indicators.
2.2 Data collection
This study was performed in the northern part of the Netherlands.
This area comprises nine hospitals providing care to children with
cancer. Concerning the structure indicators and one process indicator,
all centers were included. With regard to the process and outcome
indicators, individual patient data were collected in three centers—
University Medical Center Groningen (academic hospital, primary
pediatric oncologic treatment center), Medical Center Leeuwarden,
and Isala Zwolle (the latter two are secondary hospitals providing
pediatric oncology shared care). Eligible patients for individual patient
data collection were all children (<18 years at diagnosis) diagnosed
with cancer between January 1, 2014 and December 31, 2015, and
who were treated in the participating centers. Data collection took
place in August 2017; thus, most included patients had (nearly)
finished treatment.
To evaluate the structure and process indicators, a questionnaire
was completed by pediatricians who provided local care for children
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with cancer in all nine hospitals. To gather information for the outcome
indicators (ie, the individual patient data), electronic patient records
(EPR) in the three participating hospitals were consulted by the main
researcher (S.B.). In order to identify patients who were admitted
for an episode of FN, we checked the laboratory records of eligible
children. As it is standard care for children with cancer who present
with fever in the hospital to have a blood culture drawn (to identify
possible causalmicroorganisms), we used these blood cultures to iden-
tify febrile episodes. We then checked whether these febrile episodes
were neutropenic (neutrophils < 500/𝜇L, or when not determined,
leukocytes<1000/𝜇L). “Admission”was defined as “a hospitalization in
which an episode of FN occurs,” to also include children who were not
primarily hospitalized for FN but did develop fever during admission.
For the included patients, we extracted basic demographic factors
from the EPR—gender, date of birth, diagnosis, date of diagnosis,
and treatment protocol. Additionally, variables that describe the
characteristics of the FN episode were extracted—antibiotics used,
additional testing performed, and occurrence of complications
(defined as intensive care unit [ICU] admittance and inpatient death).
In case of different local FN protocols, we would compare the findings
between the three hospitals. In addition, all identified deviations from
the DCOG guideline as well as all episodes with a complication were
further investigated individually in a qualitative manner.
2.3 Statistical analyses
Results are presented in a descriptive manner. Rate-based indicators
are presented in percentages. Possible differences between hospitals,
if any, were analyzed bymeans of a chi-squared test. Confidence inter-
vals (95%CI) were computed according to theWilsonmethod as small
numbers of successes and/or failures were anticipated.15 Statistical
analyses were performed using Stata Statistical Software, Release 15
(StataCorp LLC, College Station, TX).
2.4 Ethical approval
The local medical research ethics committee (MREC) of the University
Medical Center Groningen judged that this study did not fit the scope
of the Medical Research Involving Human Subjects Act according to
the Declaration of Helsinki; thus, it was not obligatory to seek formal
approval of theMREC.
3 RESULTS
In all, seven indicators were developed (Table 1). The operational-
ized structure indicators concerned the local recommendation on
antimicrobial policy of FN. With regard to the process indicators, we
evaluated the administered antibiotics in FN episodes without bac-
terial focus, which means no source of infection at the onset of fever
(DCOG guideline—monotherapy with ceftazidim) and the conduction
of additional testing in neutropenic children under antibiotics with
persistent (>96h since onset) fever (DCOGguideline—performance of
high-resolution computed tomography [HRCT] thorax and, if indicated,
broncho-alveolar lavage [BAL] just after 96 h).16 In other words, one
TABLE 1 The developed structure, process, and outcome
indicators
Structure Indicators
Indicator 1 Having a general recommendation on the
antimicrobial policy of FN in childrenwith cancer
1. No recommendation
2. Verbal agreement
3. Written recommendation in own document
system
4. According to the DCOG guideline





Indicator 3 Percentage of febrile neutropenia episodes
withoutmicrobial focus, which are treatedwith
ceftazidim
Numerator The number of FN episodes withoutmicrobial
focus, for which patients received ceftazidim
according to the DCOG guideline
Denominator All episodes of FNwithoutmicrobial focus
Indicator 4 Percentage of febrile episodes in neutropenia
with persistent fever without focus (>96 h), in
which an HRCT or BALwas performed
Numerator The number of persistent FN episodes without
microbial focus, in which an HRCT/BALwas
performed
Denominator All persistent FN episodes withoutmicrobial
focus
Outcome indicators
Indicator 5 The percentage of clinical FN episodes in children
with cancer, in which a patient is admitted to
the ICU
Numerator The number of clinical FN episodes in children
with cancer, in which a patient is admitted to
the ICU
Denominator All clinical FN episodes
Indicator 6 Cumulative incidence of childrenwith cancer who
die during a clinical FN episode
Numerator The number of childrenwith cancer who die
during a clinical FN episode
Denominator The total number of childrenwith cancer
diagnosed between January 1, 2014 and
December 31, 2015, with the childrenwith
cancer who die not during a clinical FN episode
as competing interest
Indicator 7 The percentage of clinical FN episodes of which
patients have died
Numerator The number of clinical FN episodes of which
patients have died
Denominator The total number of clinical FN episodes
of both equals success. For numerators and denominators, see Table 1.
With regard to outcome indicators, we registered ICU admittance and
inpatient mortality, the latter being interpreted with two indicators—
one focusing on cumulative incidence of death during FN (with death
not during FN as competing event) in children with cancer and one
focusing onmortality rate in febrile neutropenic episodes.
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Number of total FN episodes per hospital 119 (100)
UMCG 88 (74.0)
Medical Center Leeuwarden 18 (15.2)
Isala Zwolle 13 (10.9)
Relapsed disease 10 (16.9)







Number of ICU admittances 22 (100)
With focus 6 (27.3)
Without focus 16 (72.7)
3.1 Structure indicators (all hospitals)—indicators
1 and 2
Six (including all three hospitals where individual patient data were
collected) out of nine hospitals stated they were using the DCOG
guideline on FN for local care recommendations. The three remaining
hospitals stated their local recommendations for FN conformed to
the workbook Supportive Care Pediatric Oncologywritten by the DCOG
in 2005. All nine hospitals however stated that their first choice of
antibiotics in episodes without focus was ceftazidim (in line with
DCOG guideline recommendation).
3.2 Process indicators—indicators 3 and 4
A total of 181 childrenwere diagnosedwith cancer between January1,
2014andDecember31, 2015 in thenorthof theNetherlands, ofwhom
30 had died (16.6%) at the moment of data collection. In total, 119
FN episodes occurred in 59 patients, ranging from one to six episodes
(median 2) per patient (see Table 2 for characteristics). Three of the 59
included patients had died during an FN episode, one in a shared-care
hospital and two in the academic hospital.
Of the 119 FN episodes, 108 were without focus. These were all
(100%; 95% CI 0.97-1.00) treated with ceftazidim according to the
DCOG guideline. Furthermore, 14 episodes of persistent fever (>96 h)
occurred, inwhichwe found that a timelyHRCT thorax and/orBALwas
performed in 12 of the 14 episodes (85.7%; 95% CI 0.6-0.96). In both
cases where additional testing deviated from the DCOG guideline, the
HRCT and/or BAL was performed 2 days over time without any reg-
istered reason for delay. Both patients were (since fever onset) admit-
ted to the academic hospital; thus, transfer froma shared-care hospital
could not have caused the delay.
3.3 Outcome indicators—indicators 5, 6, and 7
Of all 119 episodes of FN, 22 (18.5%; 95%CI 0.13-0.26) resulted in ICU
admittance, of which 16 were without focus at the onset of the fever.
In all 22 episodes, the childrenwere initially admittedwith fever to the
academic hospital (only hospital with a pediatric ICU in the area). We
could not determinewhether this was related to the severity of the FN
episodes (this was not studied).
Of the 181 children diagnosed with cancer, three died during FN
admission. Correspondingly, the cumulative incidence of death during
FN was 1.74% (indicator 6). In addition, this means that three of 119
FN episodes resulted in death (2.5%; 95%CI 0.01-0.07) (indicator 7).
We tried to elucidate the cause of death for these three children.
Diagnoses were ALL (n = 1), mixed phenotype acute leukemia (n = 1),
and osteosarcoma (n = 1). One patient died in a shared-care hospital
(seconnd episode of FN) due to a fulminant Escherichia Coli sepsis,
before pediatric intensivists of the academic hospital arrived onsite
to transfer the child to the ICU. Two patients died in the academic
hospital; one patient (fourth episode) died of E. Coli sepsis, and for
the other patient (fifth episode) the cause of death remains unknown
(negative blood cultures, no approval of parents for autopsy).
4 DISCUSSION
In this study, we developed indicators to evaluate the quality of care
concerning FN episodes in children with cancer. We found that six out
of nine hospitals in the north of the Netherlands use the appropriate
DCOG guideline on FN. Furthermore, the recommendation of this
guideline to use monotherapy with ceftazidim in episodes without
focus was accurately adhered to, and the recommendation to perform
additional testing in prolonged fever episodes was largely adhered to.
However, FN still puts a large burden on medical, social, and financial
aspects; in our cohort of 181 children with cancer, 119 admissions
because of FN episodes occurred. Additionally, one in five FN episodes
resulted in ICU admission and one in 40 FN episodes resulted in death.
4.1 Implementation of the DCOG guideline
Overall, it can be said that the DCOG guideline on FN is implemented
quite successfully, as it has been shown in the three largest hospi-
tals that if hospitals indeed use the DCOG guideline for guidance,
the adherence is excellent considering the choice of antibiotics in FN
episodes without focus (100%).
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Six out of nine hospitals used theDCOGguideline for guidance. The
other three used an outdated workbook (published in 2005), in which
the recommendation on the use of antibiotics in febrile episodes with-
out focuswas ceftazidim aswell. Even thoughwedid not performa for-
mal analysis of which recommendations were used in certain hospitals
andwhether these recommendations differed from the newguidelines
or not, there is a risk of suboptimal care as these guidelines are out-
dated and new guidelines are already in use.
In our study, ICU admission occurred in 18.5% of all episodes. Com-
parable studies are scarce, butwe found that in adultswith cancer, 14%
of episodes with FN resulted in ICU admittance.17
Furthermore, cumulative incidence of death during an FN episode
was 1.74% in our cohort. In a study on infection-related deaths in chil-
dren with ALL, the mortality rate due to sepsis was 2.4%.6 With this
informationbeinggiven,wemaydrawtheconclusion that thequalityof
carewith regard to the outcomes of FN in the north of theNetherlands
is comparable to that found in the (sparsely available) literature. Nat-
urally, this study only provided us with baseline measurements, which
will be repeated to evaluate quality of care over time.
4.2 Limitations
We chose a balanced approach of rigorous and pragmatic indicator
development. Therefore, this study can be seen as a practice example
of how to develop high-quality indicators and produce baseline mea-
surements in a relatively short period of time. However, the content of
these indicatorsmight differ from those that are developed usingmore
rigorous and time-consumingmethods.
Another limitation is the nature of retrospectively acquired data.
While this study benefits from the advantages of this type of data col-
lection (eg, instant availability), data were restricted to those already
collected by routine clinical care. Therefore, in a follow-up project, we
will identify the variables needed in the EPR and structurally collect
prospective data.
As some of the included patients had relapsed before data collec-
tion, we worried this might introduce bias and hence limit generaliz-
ability. Therefore, we performed a sensitivity analysis wherein all FN
episodes that occurred during relapse (n = 12) were removed, which
did not change our findings meaningfully.
In addition, we only included the three largest centers for individual
patient data collection; we did not perform this in the six smaller cen-
ters. Theremight have been admissions due to FN in these centers that
we were not aware of. If anything, this would mean that our identified
incidence (and thus burden) of FNmight even be an underestimation.
Lastly, this first implementation was only done in the north of the
Netherlands, which is a relatively small area. Thus, it might be possible
that the nationwide quality of the provision of supportive care differs
from that in our findings.
4.3 Recommendations for future use of indicators
in FN
The developed indicators have been shown to be useful and can
therefore be implemented nationally (and internationally). In the
Netherlands, all children with cancer will predominantly be treated
at the Princess Máxima Center for Pediatric Oncology (opening mid-
2018) in collaboration with shared-care centers. To evaluate and com-
pare the quality of care in all the hospitals involved in treating children
with FN, measuring these indicators will be important. However, using
our methods, this will be costly in terms of both time and money, as
every single patient with an FN episode has to be selected by hand.
Therefore, we recommend saving all the information needed for these
indicators electronically, automatically, and nationally. Furthermore, it
will be important that guidelines be linked to the EPR. An automated
programshould be interwovenwith theEPR to stimulate care basedon
current guidelines and to evaluate the indicators. This program might
also facilitate necessary checks (eg, “is the patient indeed febrile?”).
Moreover, we should develop a learning cycle to get insight on why
some children suffer from (major) adverse effects while others do not.
This will be essential in order to improve the quality of supportive care
in children with cancer.
5 CONCLUSION
This study on the implementation of indicators for FN served as a
baseline measurement of quality of care. We found that guidelines
are suboptimally implemented: three out of nine hospitals used an
outdated workbook. The relatively high rates of mortality and ICU
admissions show that FN still puts great burden on children with
cancer.
Ideally, these indicators should be implemented nationwide in the
Netherlands and all the informationneeded for these indicators should
be saved nationally and electronically in order to keep track of changes
in quality of care concerning FN. Also, we would like to repeat this
study in 5 years and expand it to all Dutch hospitals caring for chil-
dren with cancer, to get a more comprehensive overview and to iden-
tify any improvements or deteriorations. In addition, this study serves
as a practical example of a rigorous but pragmatic method of devel-
opment of indicators and we encourage this to be replicated in other
fields of (pediatric) medicine as well.
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